Hirsch, PharmD

20 Pages·2016·0.12 MB·English

Elizabeth B. Hirsch, PharmD, BCPS
Assistant Professor
Department of Pharmacy and Health Systems Sciences
Northeastern University
360 Huntington Avenue, R218 TF, Boston, MA 02115
Phone: [phone] Fax: [phone] Email: [email protected]

EDUCATION/EMPLOYMENT HISTORY

Education

2008-2010 Infectious Diseases Pharmacotherapy Fellowship
St. Luke’s Episcopal Hospital /
University of Houston College of Pharmacy; Houston, TX

2007-2008 ASHP Accredited PGY1 Pharmacy Residency
St. Luke’s Episcopal Hospital; Houston, TX

2007 Doctor of Pharmacy
Bachelor of Health Sciences
Creighton University School of Pharmacy and Health Professions; Omaha, NE

Employment history

2011-Present Assistant Professor
Northeastern University; Boston, MA

2011-Present Clinical Pharmacist, Infectious Diseases / Antimicrobial Stewardship Team
Beth Israel Deaconess Medical Center; Boston, MA

2010-2011 Research Assistant Professor
University of Houston College of Pharmacy; Houston, TX

Licensures and certifications

2011-Present Massachusetts State Board of Pharmacy, Licensed Pharmacist
2009-Present Board Certified Pharmacotherapy Specialist
2009-Present Texas State Board of Pharmacy, Pharmacist Preceptor
2007-Present Texas State Board of Pharmacy, Licensed Pharmacist
Elizabeth Hirsch (Feb 2016) 2
SCHOLARSHIP/RESEARCH

Major Areas of Research and Scholarship:

Infectious Diseases Translational Research
1. Pharmacokinetics / pharmacodynamics of antimicrobials (PK/PD)
2. Antimicrobial susceptibility testing (AST)
3. Rapid diagnostics for bacterial infections (RD)
4. Clinical outcomes of infection (CO)

Honors and awards

2014 Mutual Mentoring Advancement Program (M2AP) grant, Northeastern University
2013 The Rho Chi Society induction
2013 The Gerald Schumacher Pharmacy Faculty Award, Northeastern University
School of Pharmacy
2012 Society of Infectious Diseases Pharmacists (SIDP) Young Investigator
Research Award
2010 ASHP Best Practices Award (CASE)
2010 American Society for Microbiology ICAAC Fellows Grant Program
2009 American College of Clinical Pharmacy travel grant
2005 Phi Lambda Sigma-National Pharmacy Leadership Society induction

Refereed articles

2016 Hirsch EB, Zucchi PC, Chen A, Raux BR, Kirby JE, McCoy C, Eliopoulos GM.
Susceptibility of multidrug-resistant Gram-negative urine isolates to oral antibiotics.
Antimicrobial Agents and Chemotherapy 2016 [epub ahead of print].

Patel TS, Cottreau JM, Hirsch EB, Tam VH. Impact of glycemic control on outcomes of
patients with Pseudomonas aeruginosa bacteremia. Diagnostic Microbiology and
Infectious Diseases 2016; 84(2):155-8.

2015 Biehle LR, Cottreau JM, Thompson DJ, Filipek RL, O’Donnell JN, Lasco TM, Mahoney
MV, Hirsch EB. Outcomes and risk factors for mortality among patients treated with
carbapenems for Klebsiella spp. bacteremia. PLOS One 2015; Nov 30;10(11):e0143845.

Hirsch EB, Raux BR, Zucchi PC, Kim Y, McCoy C, Kirby JE, Wright SB, Eliopoulos
GM. Activity of fosfomycin and comparison of multiple susceptibility testing methods
against contemporary urine isolates. International Journal of Antimicrobial Agents 2015;
45(6):642-7.
Elizabeth Hirsch (Feb 2016) 3
Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and
ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination
agents for the treatment of resistant Gram-negative bacterial infections. International
Journal of Antimicrobial Agents 2015; 46(3):266-71.

Aitken SA, Altshuler J, Guervil DA, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD,
Tam VH. Cefepime free minimum concentration to minimum inhibitory concentration
(fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial
pneumonia. International Journal of Antimicrobial Agents 2015; 45(5):541-544.

2014 Hirsch EB, Raux BR, Lancaster JW, Mann RL, Leonard SN. Surface microbiology of
the iPad tablet computer and the potential to serve as a fomite in both inpatient practice
settings as well as outside of the hospital environment. PLoS One 2014; 9(10): e111250.

Hirsch EB, Chang KT, Zucchi PC, Francoeur DN, Ledesma KR, Tam VH, Lasco TM.
An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae
carbapenemase (KPC)-producing Enterobacteriaceae. Journal of Infection and
Chemotherapy 2014; 20(3):224-227.

2013 Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, Tam VH. Assessment of
antimicrobial combinations for KPC-producing Klebsiella pneumoniae. Journal of
Infectious Diseases 2013; 207(5):786-793.

2012 Tam VH, Hirsch EB, Lasco TM, Chang KT, Gentry LO, Palmer HR. Correlation of
hospital carbapenem consumption and resistance trends in gram-negative bacteria.
Annals of Pharmacotherapy 2012; 46(7-8):1120-1122.

Tran TT, Palmer HP, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW.
Evaluation of a daptomycin dose optimization protocol: a potential policy for antibiotic
stewardship programs. American Journal of Health-System Pharmacy 2012; 69(11):979-
984.

Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro
activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem
against carbapenem resistant Gram-negative bacteria. Antimicrobial Agents and
Chemotherapy 2012; 56(7):3753-3757.

Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolau M, Tam VH. A novel
modeling framework to guide design of optimal dosing strategies for beta-lactamase
inhibitors. Antimicrobial Agents and Chemotherapy 2012; 56(5):2237-2240.

Hirsch EB, Cottreau JM, Caeiro JP, Johnson ML, Tam VH. A model to predict
mortality following Pseudomonas aeruginosa bacteremia. Diagnostic Microbiology and
Infectious Diseases 2012; 72(1):97-102.
Elizabeth Hirsch (Feb 2016) 4
2011 Hirsch EB, Cottreau JM, Ikwuagwu JO, Lusardi KT, Mohr JF, Rodriguez SM, Shah DN,
Tran TT, on behalf of the Houston Infectious Diseases Network. Significant publications
in infectious diseases pharmacotherapy in 2010. American Journal of Health-System
Pharmacy 2011; 68(21):2075-2085.

Hirsch EB, Chang KT, Lasco TM, Caeiro JP, Tam VH. Emergence of KPC-producing
Klebsiella pneumoniae (KPC-Kp) in Texas. Diagnostic Microbiology and Infectious
Diseases 2011; 69(2):234-235.

2010 Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection
on patient outcomes. Expert Review of Pharmacoeconomic Outcomes Research 2010;
10(4):441-451.

Palmer HR, Cottreau JM, Garey KG, Hirsch EB, Musick WL, Tam VH, Yeh RF, on
behalf of the Houston Infectious Diseases Network. Significant publications on
infectious diseases pharmacotherapy in 2009. American Journal of Health-System
Pharmacy 2010;67(15): e34-42.

Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae
carbapenemases (KPCs): an emerging cause of multidrug-resistant infections. Journal of
Antimicrobial Chemotherapy 2010; 65(6):1119-1125.

2009 Kuper K, Hirsch EB, Tam VH, on behalf of the Houston Infectious Diseases Network.
Significant publications on infectious diseases pharmacotherapy in 2008. American
Journal of Health-System Pharmacy 2009; 66(19): 1726-1734.

Book chapters / contributions

Antiparasitic agents, Chapter 34. Clinical significance and scenario. In: Foye’s Principles of
Medicinal Chemistry, 7th edition. Lippincott Williams and Wilkins, WoltersKluwer Health.
Copyright 2013.

Presentations

Invited speaker - National

2015 Understanding and managing multidrug-resistant Acinetobacter infections. Presented at
the Medical City Dallas Hospital. Dallas, TX. November 12, 2015.

Understanding and managing multidrug-resistant Acinetobacter infections. Presented at
Stephen Pyles. Dallas, TX. November 12, 2015.

Understanding and managing multidrug-resistant Acinetobacter infections. Presented to
the Houston Infectious Diseases Network. Houston, TX. November 11, 2015.
Elizabeth Hirsch (Feb 2016) 5
2012 Gram-negative infections and emergence of resistance: is one drug enough? Presented at
the American Society of Health-System Pharmacists Midyear Clinical Meeting, Las
Vegas, NV. December 4, 2012.

Invited speaker – Regional / local

2014 Management of Gram-negative infections. Presented at Cubist Pharmaceuticals for the
post-doctoral fellowship program. Lexington, MA. July 10, 2014.

2012 Resistant Enterobacteriaceae infections: have we lost the battle? Presented at the
The Council of Boston Teaching Hospitals and Northeastern University School of
Pharmacy: Pharmacy Grand Rounds, Boston, MA. January 9, 2013.

2012 Strategies for management of resistant Gram-negative infections in the ICU. The 9th
Annual Critical Care Symposium, Boston, MA. May 8, 2012.

Refereed Conference Presentations - International

2016 Hirsch EB, Arriola T, Zucchi PC, Chen A, Lasco TM, Kirby JE, Leonard SN, Krevolin
K, Emery CL, Bias T. Activity of ceftazidime/avibactam and ceftolozane/tazobactam
against multidrug-resistant gram-negative isolates. Accepted abstract, Poster
Presentation, 26th European Congress of Clinical Microbiology and Infectious Diseases.
Amsterdam, Netherlands, April 2016.

2015 Hirsch EB, Raux BR, Zucchi PC, Kim Y, McCoy, Wright SB, Eliopoulos GM.
Susceptibility of multidrug-resistant (MDR) Gram-negative urinary pathogens to oral
antibiotics at a large academic medical center. Accepted abstract, Poster Presentation,
25th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen,
Denmark, April 2015.

2012 Tam VH, Hirsch EB, Lasco TM, Chang KT, Gentry LO, Palmer HR. Correlation of
hospital carbapenem consumption and resistance trends in Gram-negative bacteria. To be
presented as an oral presentation at the 12th Asian Conference on Clinical Pharmacy.
Hong Kong SAR, China, July 2012.

Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, Tam VH. Assessment of
antimicrobial combinations for KPC-producing Klebsiella pneumoniae infections.
Accepted abstract, Poster Presentation, 22nd European Conference on Clinical
Microbiology and Infectious Diseases. London, UK, March 2012.

2011 Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. Combined
activity of MK-7655 and imipenem against carbapenem resistant Pseudomonas
aeruginosa. Accepted abstract, Poster Presentation, 21st European Conference on
Clinical Microbiology and Infectious Diseases / 27th International Congress of
Chemotherapy. Milan, Italy, May 2011.
Elizabeth Hirsch (Feb 2016) 6
Refereed Conference Presentations - National

2016 Chen A, Lane BV, Wright SB, Yassa DS, Snyder GM, Hirsch EB. Delayed processing
of simulated duodenoscope and patient cultures yields viable bacteria. Accepted abstract,
Poster Presentation, The Society for Healthcare Epidemiology of America Spring 2016
Conference. Atlanta, GA, May 2016.

Snyder GM, Wright SB, Smithey A, Mizrahi M, Sheppard M, Hirsch EB, Sawhney M.
Prospective randomized trial comparing three duodenoscope high-level disinfection and
sterilization procedures. Accepted abstract, Poster Presentation, The Society for
Healthcare Epidemiology of America Spring 2016 Conference. Atlanta, GA, May 2016.

Olafsdottir LB, Wright SB, Smithey A, Hirsch EB, Chen A, Lane BV, Snyder GM.
Adenosine triphosphate quantification correlates poorly with microbial contamination of
duodenoscopes. Accepted abstract, Poster Presentation, The Society for Healthcare
Epidemiology of America Spring 2016 Conference. Atlanta, GA, May 2016.

2015 Burrelli CC, Snyder G, Gold H, McCoy C, Mahoney MG, Hirsch EB. Treatment
outcomes with nafcillin versus cefazolin for methicillin-susceptible Staphylococcus
aureus bloodstream infections. Accepted abstract, Poster Presentation, 50th ASHP
Midyear Clinical Meeting. New Orleans, LA, December 2015.

Cote MA, Kahura P, Kreider E, Mahoney MV, McCoy C, Hirsch EB. Appropriateness
of discharge therapy and clinical characteristics of hospitalized cellulitis patients admitted
through the emergency department. Accepted abstract, Student Poster Presentation, 50th
ASHP Midyear Clinical Meeting. New Orleans, LA, December 2015.

Aljefri D, Adra M, McCoy C, Hirsch EB, Mahoney MV. Clinical outcomes of
daptomycin therapy based on dosing body weight versus total body weight. Accepted
abstract, Poster Presentation, 50th ASHP Midyear Clinical Meeting. New Orleans, LA,
December 2015.

Arriola T, Zucchi PC, Lasco TM, Leonard SN, Hirsch EB. Susceptibility of multidrug-
resistant (MDR) Gram-negative isolates to ceftazidime-avibactam (CZA) and
ceftolozane-tazobactam (C/T). Accepted abstract, Poster Presentation, 55th Interscience
Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, September
2015.

Lee KC, McCoy C, Snyder GM, Hirsch EB, Mahoney MV. High- versus low-dose
sulfamethoxazole/trimethoprim (SMZ/TMP) for the treatment of Stenotrophomonas
maltophilia pneumonia. Accepted abstract, Poster Presentation, 55th Interscience
Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, September
2015.

Spaulding A, Mahalingam P, Takrouri K, Cleary DC, Zucchi PC, Koleva B, Beuning PJ,
Hirsch EB, Aggen JB. Optimization of gram-negative activity using a strategy
Elizabeth Hirsch (Feb 2016) 7
emphasizing multicharge character: progress against Escherichia coli in the
oxazolidinone (OXAZ) class via dual A and C-ring modifications. Accepted abstract,
Poster Presentation, 55th Interscience Conference on Antimicrobial Agents and
Chemotherapy. San Diego, CA, September 2015.

Takrouri K, Spaulding A, Cooper H, Cleary DC, Zucchi PC, Tear W, Koleva B, Beuning
PJ, Hirsch EB, Aggen JB. Optimizing gram-negative antibacterial (AB) activity using a
strategy emphasizing appropriate physicochemical properties: progress against
Escherichia coli in the oxazolidinone (OXAZ) class via multiple C-ring modifications.
Accepted abstract, Poster Presentation, 55th Interscience Conference on Antimicrobial
Agents and Chemotherapy. San Diego, CA, September 2015.

Raux BR, Lyman A, Walker E, Liscio J, McCoy C, Eliopoulos GM, MD, Hirsch EB.
Appropriateness of treatment of Gram-negative bacteriuria in a large academic hospital.
Accepted abstract, Poster Presentation, IDWeek. San Diego, CA, October 2015.

2014 Lee KC, McCoy C, Hirsch EB, Snyder GM, Mahoney MV. The impact of high-dose
versus low-dose sulfamethoxazole-trimethoprim in the treatment of Stenotrophomonas
maltophilia pneumonia. Accepted abstract, Poster Presentation, 49th ASHP Midyear
Clinical Meeting. Anaheim, CA, December 2014.

Hirsch EB, Raux BR, Zucchi PC, Kim Y, McCoy C, Wright SB, Eliopoulos GM.
Activity of fosfomycin against contemporary urinary pathogens collected from a Boston
teaching hospital. Accepted abstract, Poster Presentation, 54th Interscience Conference
on Antimicrobial Agents and Chemotherapy. Washington, DC, September 2014.

Jonchhe S, Giancola S, Golik Mahoney MV, Qian Q, McCoy C, Snyder S, Hirsch EB.
Outcomes of carbapenem beta-lactam (CBL) versus non-carbapenem beta-lactam (N-
CBL) treatment for third-generation cephalosporin-resistant (3GCR) Enterobacteriaceae
bloodstream infections (BSI). Accepted abstract, Poster Presentation, 54th Interscience
Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, September
2014.

Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD,
Tam VH. Cefepime free minimum concentration (fCmin) to minimum inhibitory
concentration (MIC) ratio predicts clinical failure in patients with Gram-negative
bacterial pneumonia. Accepted abstract, Poster Presentation, 54th Interscience
Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, September
2014.

2013 Dziuba K, Golik Mahoney MV, McCoy C, Hirsch EB. Daptomycin versus linezolid for
the treatment of vancomycin-resistant enterococcal urinary tract infections. Accepted
abstract, Poster Presentation, 48th ASHP Midyear Clinical Meeting. Orlando, FL,
December 2013.
Elizabeth Hirsch (Feb 2016) 8
Giancola S, McCoy C, Golik Mahoney M, Hirsch EB. Patient characteristics and
antibiotic prescribing patterns of third-generation cephalosporin-resistant (3GCR)
Escherichia coli bloodstream infections (BSI). Accepted abstract, Poster Presentation,
48th ASHP Midyear Clinical Meeting. Orlando, FL, December 2013.

Jonchhe S, Golik Mahoney M, McCoy C, Hirsch EB. Efficacy of cefepime therapy for
treatment of Enterobacteriaceae bloodstream infections (BSI): an evaluation of the
revised susceptibility breakpoints. Accepted abstract, Poster Presentation, 48th ASHP
Midyear Clinical Meeting. Orlando, FL, December 2013.

Hirsch EB, Lancaster JW, Raux B, Mann R, Leonard SN. Surface microbiology of the
iPad Tablet computer and the potential to serve as a fomite. Accepted abstract, Poster
Presentation, IDWeek. San Francisco, CA, October 2013.

Biehle L, Cottreau JM, Thompson DJ, Filipek RL, O’Donnell JN, Lasco TM. McCoy C,
Golik Mahoney M, Hirsch EB. Outcomes after carbapenem treatment for Klebsiella
bacteremia: a multicenter assessment of the updated susceptibility breakpoints. Accepted
abstract, Poster Presentation, 53rd Interscience Conference on Antimicrobial Agents and
Chemotherapy. Denver, CO, September 2013.

2012 Filipek RL, Thompson DJ, Golik Mahoney MV, McCoy C, Hirsch EB. Clinical
experience with oral fosfomycin for urinary tract infections. Accepted abstract,
Poster Presentation, 47th American Society of Health System Pharmacists Midyear
Clinical Meeting. Las Vegas, NV, December 2012.

Hirsch EB, Chang KT, Francoeur D, Ledesma KR, Tam VH, Lasco TM. An evaluation
of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase
(KPC)-producing Enterobacteriaceae. Accepted abstract, Poster Presentation, 52nd
Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco,
CA, September 2012.

Biehle L, Hirsch EB, Cottreau JM. Outcomes following carbapenem therapy for
Klebsiella bacteremia: an assessment of the updated susceptibility breakpoints. Accepted
abstract, Poster Presentation, 52nd Interscience Conference on Antimicrobial Agents and
Chemotherapy. San Francisco, CA, September 2012.

Mordino J, Hirsch EB, Golik Mahoney M. Creatinine phosphokinase (CPK) elevations
in patients on daptomycin with or without a statin. Accepted abstract, Poster
Presentation, 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
San Francisco, CA, September 2012.

2011 Phe K, Cao H, Cottreau JM, Tam VH, Hirsch EB. Comparison of morbidity and
mortality after Klebsiella pneumoniae carbapenemase (KPC)-producing bloodstream
infection stratified by level of carbapenem resistance. Accepted abstract, Poster
Presentation, 46th American Society of Health System Pharmacists Midyear Clinical
Meeting. New Orleans, LA, December 2011.
Elizabeth Hirsch (Feb 2016) 9
Hirsch EB, Chang KT, Cao H, Tam VH, Lasco TM. Prevalence of Klebsiella
pneumoniae carbapenemase (KPC)-harboring Enterobacteriaceae bloodstream isolates at
a large tertiary care center. Accepted abstract, Poster Presentation, 51st Interscience
Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2011.

Hirsch EB, Phe K, Cottreau JM, Lasco TM, Tam VH. Clinical outcomes following
Klebsiella pneumoniae carbapenemase (KPC)-harboring Enterobacteriaceae bloodstream
infections. Accepted abstract, Poster Presentation, 51st Interscience Conference on
Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2011.

Bhagunde P, Chang KT, Hirsch EB, Nikolau M, Tam VH. A novel modeling
framework to guide optimal dosing of beta-lactamase inhibitors. Accepted abstract,
Platform Presentation, 51st Interscience Conference on Antimicrobial Agents and
Chemotherapy. Chicago, IL, September 2011.

Cottreau JM, Patel T, Hirsch EB, Caeiro JP, Tam VH. Impact of glycemic control on
outcomes of Pseudomonas aeruginosa (PA) bacteremia. Accepted abstract, Poster
Presentation, 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
Chicago, IL, September 2011.

Tran TT, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey
KG. High dose daptomycin (≥ 8 Mg/kg) for the treatment of non-urinary vancomycin-
resistant enterococcal infections. Accepted abstract, Poster Presentation, 51st Interscience
Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2011.

2010 Hirsch EB, Chang KT, Lasco TM, Tam VH. Emergence of KPC-producing Klebsiella
pneumoniae isolates in the Texas Medical Center (TMC). Accepted abstract, Platform
Presentation, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Boston, MA, September 2010.

Hirsch EB, Cottreau JM, Caeiro JP, Johnson ML, Tam VH. Prospective validation of a
model to predict mortality following Pseudomonas aeruginosa (PA) bacteremia.
Accepted abstract, Poster Presentation, 50th Interscience Conference on Antimicrobial
Agents and Chemotherapy. Boston, MA, September 2010.

Hirsch EB, Ledesma KR, Chang KT, Motyl MR, Tam VH. In vitro activity of MK-7655
in combination with imipenem (IPM) against carbapenem resistant Gram-negative
bacteria. Accepted abstract, Poster Presentation, 50th Interscience Conference on
Antimicrobial Agents and Chemotherapy. Boston, MA, September 2010.

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey
KW. Evaluation of a daptomycin PK/PD dose optimization protocol. Accepted abstract,
Platform Presentation, 50th Interscience Conference on Antimicrobial Agents and
Chemotherapy. Boston, MA, September 2010.

2009 Hirsch EB, Neuhauser MM, Dodds Ashley E, Gallagher JC, Hermsen ED, DePestel DD,
Ernst EJ. History of the American College of Clinical Pharmacy's infectious diseases
Elizabeth Hirsch (Feb 2016) 10
practice and research network (ID-PRN). Accepted abstract, Poster Presentation,
American College of Clinical Pharmacy Annual Meeting. Anaheim, CA, October 2009.

Hirsch EB, Weston JS, Cottreau JM, Garey KW, Tam VH, Palmer HR. An
antimicrobial stewardship restriction protocol optimizes the use of daptomycin.
Accepted abstract, Poster Presentation, American College of Clinical Pharmacy Annual
Meeting. Anaheim, CA, October 2009.

Refereed Conference Presentations – Regional / Local

2015 Lee KC, McCoy C, Hirsch EB, Snyder GM, Mahoney MV. The impact of high-dose
versus low-dose sulfamethoxazole-trimethoprim in the treatment of Stenotrophomonas
maltophilia pneumonia. Accepted abstract, platform presentation, platform presentation,
34th Eastern States Conference for Residents and Preceptors. Hershey, PA, May 2015.

Raux BR, Lyman A, Walker E, McCoy C, Eliopoulos GM, Hirsch EB. Characteristics
of patients with symptomatic and asymptomatic bacteriuria caused by Escherichia coli
and Pseudomonas aeruginosa in a Boston teaching hospital. Accepted abstract, poster
presentation, Honors Evening Research Expo. Northeastern University. Boston, MA,
April 14, 2015.

Campos M, Phung A, Zucchi PC, Hirsch EB. Efficacy of antimicrobial surface testing
protocols. Accepted abstract, poster presentation, Honors Evening Research Expo.
Northeastern University. Boston, MA, April 14, 2015.

Raux BR, Lyman A, Walker E, McCoy C, Eliopoulos GM, Hirsch EB. Characteristics
of patients with symptomatic and asymptomatic bacteriuria caused by Escherichia coli
and Pseudomonas aeruginosa in a Boston teaching hospital. Accepted abstract, poster
presentation, RISE: 2015. Northeastern University. Boston, MA, April 9, 2015.

Raux BR, Zucchi PC, Campos M, Phung A, Hirsch EB. Development of Galleria
mellonella model system to study Carbapenem-Resistant Enterobacteriaceae (CRE)
Pathogenesis and Treatment. Accepted abstract, poster presentation, RISE: 2015.
Northeastern University. Boston, MA, April 9, 2015.

Campos M, Phung A, Zucchi PC, Hirsch EB. Efficacy of antimicrobial surface testing
protocols. Accepted abstract, poster presentation, RISE: 2015. Northeastern University.
Boston, MA, April 9, 2015.

Sabhachandani P, Sarkar S, Cohen N, Hirsch EB, Kirby JE, Konry T. ScanDrop
diagnostic approach for detection of bacterial infection markers. Accepted abstract,
poster presentation, RISE: 2015. Northeastern University, Boston, MA, April 9, 2015.

2014 Jonchhe S, Giancola S, Golik Mahoney MV, Qian Q, McCoy C, Snyder S, Hirsch EB.
Outcomes of carbapenem beta-lactam (CBL) versus non-carbapenem beta-lactam (N-